SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.43 Billion KRW | -29.11% |
| 2022 | 17.54 Billion KRW | -60.38% |
| 2021 | 44.27 Billion KRW | -59.51% |
| 2020 | 109.35 Billion KRW | -11.61% |
| 2019 | 123.72 Billion KRW | -2.23% |
| 2018 | 126.54 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 80 Billion KRW | 0.0% |
| 2024 Q1 | 80 Billion KRW | 0.0% |
| 2023 Q1 | 16.93 Billion KRW | -3.45% |
| 2023 FY | 12.43 Billion KRW | -29.11% |
| 2023 Q4 | 12.43 Billion KRW | -7.99% |
| 2023 Q3 | 13.51 Billion KRW | -10.74% |
| 2023 Q2 | 15.14 Billion KRW | -10.61% |
| 2022 Q3 | 16.74 Billion KRW | -9.8% |
| 2022 Q2 | 18.56 Billion KRW | -62.6% |
| 2022 Q1 | 49.64 Billion KRW | 12.12% |
| 2022 FY | 17.54 Billion KRW | -60.38% |
| 2022 Q4 | 17.54 Billion KRW | 4.74% |
| 2021 Q4 | 44.27 Billion KRW | -0.84% |
| 2021 Q2 | 89.37 Billion KRW | -0.11% |
| 2021 Q3 | 44.65 Billion KRW | -50.04% |
| 2021 FY | 44.27 Billion KRW | -59.51% |
| 2021 Q1 | 89.47 Billion KRW | -18.18% |
| 2020 Q2 | 125.43 Billion KRW | -1.11% |
| 2020 FY | 109.35 Billion KRW | -11.61% |
| 2020 Q4 | 109.35 Billion KRW | -3.1% |
| 2020 Q3 | 112.86 Billion KRW | -10.02% |
| 2020 Q1 | 126.83 Billion KRW | 2.52% |
| 2019 Q2 | 128.41 Billion KRW | -1.61% |
| 2019 FY | 123.72 Billion KRW | -2.23% |
| 2019 Q3 | 127.69 Billion KRW | -0.56% |
| 2019 Q4 | 123.72 Billion KRW | -3.11% |
| 2019 Q1 | 130.51 Billion KRW | 3.13% |
| 2018 Q4 | 126.54 Billion KRW | -2.03% |
| 2018 Q3 | 129.17 Billion KRW | 0.0% |
| 2018 FY | 126.54 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 2.43 Billion KRW | -410.395% |
| Green Cross Holdings Corporation | 216.35 Billion KRW | 94.252% |
| Green Cross Holdings Corporation | 84.89 Billion KRW | 85.35% |
| Pharmicell Co., Ltd. | 390.21 Million KRW | -3086.956% |
| Green Cross Corporation | 84.89 Billion KRW | 85.35% |
| GeneOne Life Science, Inc. | 6.27 Billion KRW | -98.255% |
| Celltrion, Inc. | 99.13 Billion KRW | 87.455% |
| Samsung Biologics Co.,Ltd. | 377.39 Billion KRW | 96.705% |
| SK Biopharmaceuticals Co., Ltd. | 94.48 Billion KRW | 86.838% |
| Prestige BioPharma Limited | 40.87 Billion KRW | 69.573% |